Human Health Holdings Ltd. (HK:1419)
:1419
Want to see HK:1419 full AI Analyst Report?
1419 Stock Chart & Stats
HK$0.80
-HK$0.02(-2.63%)
At close: 4:00 PM EST
HK$0.80
-HK$0.02(-2.63%)
Day’s Range― - ―
52-Week RangeHK$0.75 - HK$1.38
Previous CloseN/A
Volume1.01M
Average Volume (3M)631.27K
Market Cap
HK$292.26M
Enterprise Value-HK$5.29M
Total Cash (Recent Filing)HK$475.56M
Total Debt (Recent Filing)HK$174.22M
Price to Earnings (P/E)10.5
Beta0.27
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)0.07
Shares Outstanding379,552,220
10 Day Avg. Volume387,000
30 Day Avg. Volume631,266
Financial Highlights & Ratios
PEG Ratio1.34
Price to Book (P/B)0.41
Price to Sales (P/S)0.49
P/FCF Ratio3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthModerate leverage and substantial equity provide durable financial flexibility. With debt-to-equity near 0.17–0.25 the company can fund operations, absorb shocks, and support dividends or opportunistic investment without immediate refinancing stress, strengthening resilience over 2–6 months.
Free Cash Flow RecoveryA clear FCF rebound in 2025 shows the business can convert profits to cash when operations stabilize. Strong recent cash generation supports reinvestment, debt servicing and shareholder returns, improving the company’s ability to execute strategic initiatives over the medium term.
Proven High-margin Track RecordHistorically high margins in 2021–2023 demonstrate underlying business model strength and operational capability. This track record implies management and the service portfolio can achieve strong returns, suggesting potential for margin normalization if headwinds abate.
Bears Say
Sharp Margin CompressionA collapse from ~18% to ~4% net margin materially reduces sustainable earnings power. If the margin reset reflects structural cost, pricing or mix shifts, it will impair ROE and free cash generation and could take many quarters to reverse, limiting medium-term profit durability.
Volatile Cash FlowIntermittent negative free cash flow in 2024 followed by a 2025 rebound indicates cash generation inconsistency. This volatility complicates budgeting and increases reliance on the balance sheet during down cycles, raising execution risk for capex, acquisitions, or steady shareholder payouts.
Revenue Weakness And Slow RecoveryA decline in revenue with only modest recovery signals demand or competitive challenges. Persistent top-line weakness limits operating leverage and margin recovery, constrains scale benefits, and makes medium-term earnings growth and cash conversion less certain absent durable revenue improvement.
Human Health Holdings Ltd. News
1419 FAQ
What was Human Health Holdings Ltd.’s price range in the past 12 months?
Human Health Holdings Ltd. lowest stock price was HK$0.75 and its highest was HK$1.38 in the past 12 months.
What is Human Health Holdings Ltd.’s market cap?
Human Health Holdings Ltd.’s market cap is HK$292.26M.
When is Human Health Holdings Ltd.’s upcoming earnings report date?
Human Health Holdings Ltd.’s upcoming earnings report date is Sep 24, 2026 which is in 95 days.
How were Human Health Holdings Ltd.’s earnings last quarter?
Human Health Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported HK$0.048 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.048.
Is Human Health Holdings Ltd. overvalued?
According to Wall Street analysts Human Health Holdings Ltd.’s price is currently Overvalued.
Does Human Health Holdings Ltd. pay dividends?
Human Health Holdings Ltd. pays a Annually dividend of HK$0.03 which represents an annual dividend yield of 3.75%. See more information on Human Health Holdings Ltd. dividends here
What is Human Health Holdings Ltd.’s EPS estimate?
Human Health Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Health Holdings Ltd. have?
Human Health Holdings Ltd. has 379,552,220 shares outstanding.
What happened to Human Health Holdings Ltd.’s price movement after its last earnings report?
Human Health Holdings Ltd. reported an EPS of HK$0.048 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of Human Health Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:1419
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Human Health Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.11%
12-Months-Change
Fundamentals
Return on Equity
3.54%
Trailing 12-Months
Asset Growth
2.27%
Trailing 12-Months
Company Description
Human Health Holdings Ltd.
Operating as an investment holding company, Human Health Holdings Limited delivers a comprehensive range of healthcare services across Hong Kong. Its primary care offerings encompass a wide array of services such as routine consultations, diagnostic testing, preventive health programs, minor medical interventions, immunizations, comprehensive physical examinations, health education, and occupational health guidance. Additionally, they provide Traditional Chinese Medicine, work injury assessments, telemedicine, COVID-19 specific services, community outreach, and various health-related products and solutions. The company extends its expertise to numerous specialized medical fields, including general surgery, orthopedics and traumatology, ophthalmology, otorhinolaryngology, pediatrics, obstetrics and gynecology, gastroenterology and hepatology, respiratory medicine, cardiology, pediatric surgery, dermatology and venereology, psychiatry, radiology, urology, nephrology, neurosurgery, anaesthesiology, and oncology. Complementing these are allied health services like physiotherapy, clinical psychology, medical aesthetics, nutritional counseling, health and wellness programs, endoscopy, and advanced medical diagnostics. Furthermore, a full spectrum of dental care is available, ranging from general dentistry, dental implants (including 3D guided surgery), crowns, bridges, and periodontal treatments, to prosthodontics, oral surgery, orthodontics, and endodontics. Cosmetic options like teeth whitening, veneers, and laser dentistry are also provided, alongside advanced oral and maxillofacial surgery, CAD/CAM technology, panoramic radiography, and cone-beam CT scans. Beyond direct patient care, the company manages agreements for healthcare practitioners and offers essential medical imaging services. Established in 1997 and headquartered in Kowloon, Hong Kong, Human Health Holdings Limited maintained a network of 58 medical centers and 103 service points as of June 30, 2021. It operates as a subsidiary of Treasure Group Global Limited.
Technical Analysis
Beijing Health (Holdings) Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
UMP Healthcare Holdings Limited
―